{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:14:06Z","timestamp":1790403246138,"version":"4.1.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.taap.2019.03.018","type":"journal-article","created":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T15:35:54Z","timestamp":1553355354000},"page":"170-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Emerging role of proprotein convertase subtilisin\/kexin type-9 (PCSK-9) in inflammation and diseases"],"prefix":"10.1016","volume":"370","author":[{"given":"Madalyn","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2526-8110","authenticated-orcid":false,"given":"Salahuddin","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2019.03.018_bb0005","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/07853890.2018.1457795","article-title":"Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes","volume":"50","author":"Ahangari","year":"2018","journal-title":"Ann. Med."},{"key":"10.1016\/j.taap.2019.03.018_bb0010","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/ecam\/neh117","article-title":"Biological basis for the use of botanicals in osteoarthritis and rheumatoid arthritis: a review","volume":"2","author":"Ahmed","year":"2005","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"10.1016\/j.taap.2019.03.018_bb0015","doi-asserted-by":"crossref","first-page":"14692","DOI":"10.1073\/pnas.0802675105","article-title":"Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production","author":"Ahmed","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2019.03.018_bb0020","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.diabres.2012.01.004","article-title":"Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques","volume":"96","author":"An","year":"2012","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.taap.2019.03.018_bb0025","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMra1106700","article-title":"Proprotein convertases in health and disease","volume":"365","author":"Artenstein","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2019.03.018_bb0030","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2019.03.018_bb0035","doi-asserted-by":"crossref","first-page":"33745","DOI":"10.1074\/jbc.M112.399725","article-title":"Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation","volume":"287","author":"Benjannet","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2019.03.018_bb0040","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/eurheartj\/ehx002","article-title":"PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia","volume":"38","author":"Bernelot Moens","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.taap.2019.03.018_bb0045","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.taap.2019.03.018_bb0050","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0092-8674(00)80213-5","article-title":"The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor","volume":"89","author":"Brown","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.taap.2019.03.018_bb0055","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pharmtox-010716-104944","article-title":"PCSK9: regulation and target for drug development for dyslipidemia","volume":"57","author":"Burke","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.taap.2019.03.018_bb0060","article-title":"Scavenger receptor CD36 expression contributes to adipose tissue inflammation and cell death in diet-induced obesity","volume":"7","author":"Cai","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2019.03.018_bb0065","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.atherosclerosis.2008.02.004","article-title":"Berberine decreases PCSK9 expression in HepG2 cells","volume":"201","author":"Cameron","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.taap.2019.03.018_bb0070","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.4049\/jimmunol.0803603","article-title":"The pattern recognition receptor CD36 is a chondrocyte hypertrophy marker associated with suppression of catabolic responses and promotion of repair responses to inflammatory stimuli","volume":"182","author":"Cecil","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.taap.2019.03.018_bb0075","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MOL.0000000000000312","article-title":"Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin\/kexin type 9","volume":"27","author":"Chackerian","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.taap.2019.03.018_bb0080","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/ard.2008.101964","article-title":"Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions","volume":"68","author":"Choy","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.taap.2019.03.018_bb0085","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","article-title":"A cholesterol-lowering VLP vaccine that targets PCSK9","volume":"33","author":"Crossey","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.taap.2019.03.018_bb0090","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1111\/jcmm.12931","article-title":"Enhanced pro-protein convertase subtilisin\/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1alpha pathway in HepG2 cells","volume":"20","author":"Cui","year":"2016","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.taap.2019.03.018_bb0095","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","article-title":"PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver","volume":"35","author":"Demers","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.taap.2019.03.018_bb0100","doi-asserted-by":"crossref","first-page":"15282","DOI":"10.1038\/s41598-017-15543-x","article-title":"Identification and in vitro characterization of two new PCSK9 gain of function variants found in patients with familial hypercholesterolemia","volume":"7","author":"Di Taranto","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2019.03.018_bb0105","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/art.22809","article-title":"Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.taap.2019.03.018_bb0110","series-title":"Differential Expression of PCSK9 Modulates Infection, Inflammation and Coagulation in a Murine Model of Sepsis","author":"Dwivedi","year":"2016"},{"key":"10.1016\/j.taap.2019.03.018_bb0115","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2183\/pjab.86.484","article-title":"A historical perspective on the discovery of statins","author":"Endo","year":"2010","journal-title":"Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci."},{"key":"10.1016\/j.taap.2019.03.018_bb0120","series-title":"Reducing LDL with PCSK9 Inhibitors \u2014 The Clinical Benefit of Lipid Drugs","author":"Everett","year":"2015"},{"key":"10.1016\/j.taap.2019.03.018_bb0125","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1074\/mcp.M113.035600","article-title":"Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics","volume":"13","author":"Fagerberg","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.taap.2019.03.018_bb0130","series-title":"Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia","author":"Fala","year":"2016"},{"key":"10.1016\/j.taap.2019.03.018_bb0135","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbrc.2008.07.023","article-title":"Inflammation stimulates the expression of PCSK9","volume":"374","author":"Feingold","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2019.03.018_bb0140","first-page":"1013","article-title":"Proprotein convertase subtilisin\/kexin type 9 in rheumatoid arthritis","volume":"34","author":"Ferraz-Amaro","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.taap.2019.03.018_bb0145","series-title":"A Highly Durable RNAi Therapeutic Inhibitor of PCSK9","author":"Fitzgerald","year":"2016"},{"key":"10.1016\/j.taap.2019.03.018_bb0150","doi-asserted-by":"crossref","first-page":"e114469","DOI":"10.1371\/journal.pone.0114469","article-title":"Peptide-based anti-pcsk9 vaccines \u2013 an approach for long-term LDLc management","volume":"9","author":"Galabova","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2019.03.018_bb0155","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jcph.832","article-title":"Evaluation of evolocumab (AMG 145), a fully human anti-PCSK9 IgG2 monoclonal antibody, in subjects with hepatic impairment","volume":"57","author":"Gibbs","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2019.03.018_bb0160","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1139\/o05-155","article-title":"Expression and localization of PCSK9 in rat hepatic cells","volume":"84","author":"Grozdanov","year":"2006","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/j.taap.2019.03.018_bb0165","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bbrc.2017.02.085","article-title":"PCSK9 regulates the chemokine receptor CCR2 on monocytes","volume":"485","author":"Grune","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2019.03.018_bb0170","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijcard.2016.03.165","article-title":"Shedding light on FGF21: a potential negative regulator of PCSK9","volume":"214","author":"Guo","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.taap.2019.03.018_bb0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2121-8-9","article-title":"Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly","volume":"8","author":"Holla","year":"2007","journal-title":"BMC Cell Biol."},{"key":"10.1016\/j.taap.2019.03.018_bb0185","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem. Sci."},{"issue":"Suppl","key":"10.1016\/j.taap.2019.03.018_bb0190","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.taap.2019.03.018_bb0195","doi-asserted-by":"crossref","first-page":"489","DOI":"10.33549\/physiolres.932324","article-title":"Novel adipokine fibroblast growth factor 21 is increased in rheumatoid arthritis","volume":"61","author":"Hulejova","year":"2012","journal-title":"Physiol. Res."},{"key":"10.1016\/j.taap.2019.03.018_bb0200","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ptr.2399","article-title":"Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine","volume":"22","author":"Imanshahidi","year":"2008","journal-title":"Phytother. Res."},{"key":"10.1016\/j.taap.2019.03.018_bb0205","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1016\/j.febslet.2008.10.021","article-title":"FGF21 is an Akt-regulated myokine","volume":"582","author":"Izumiya","year":"2008","journal-title":"FEBS Lett."},{"key":"10.1016\/j.taap.2019.03.018_bb0210","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1258\/acb.2010.010087","article-title":"Effect of a splice site mutation in LDLR gene and two variations in PCSK9 gene in Tunisian families with familial hypercholesterolaemia","volume":"48","author":"Jelassi","year":"2011","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.taap.2019.03.018_bb0215","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1194\/jlr.M700443-JLR200","article-title":"Sterol-dependent regulation of proprotein convertase subtilisin\/kexin type 9 expression by sterol-regulatory element binding protein-2","volume":"49","author":"Jeong","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.taap.2019.03.018_bb0220","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/cns.12326","article-title":"Targeting CD36-mediated inflammation reduces acute brain injury in transient, but not permanent, ischemic stroke","volume":"21","author":"Kim","year":"2015","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.taap.2019.03.018_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2012.00077","article-title":"Inflammation and bone destruction in arthritis: synergistic activity of immune and mesenchymal cells in joints","volume":"3","author":"Komatsu","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.taap.2019.03.018_bb0230","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm1135","article-title":"Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins","volume":"10","author":"Kong","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.taap.2019.03.018_bb0235","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/1381612820666140825122525","article-title":"Biomarkers for radiographic progression in rheumatoid arthritis","volume":"21","author":"Krabben","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.taap.2019.03.018_bb0240","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.taap.2019.03.018_bb0245","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MOL.0b013e3281338531","article-title":"Unravelling the functional significance of PCSK9","volume":"18","author":"Lambert","year":"2007","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.taap.2019.03.018_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2008.06.010","article-title":"Molecular basis of PCSK9 function","volume":"203","author":"Lambert","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.taap.2019.03.018_bb0255","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.taap.2019.03.018_bb0260","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/dom.12819","article-title":"Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes","volume":"19","author":"Laugier-Robiolle","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.taap.2019.03.018_bb0265","doi-asserted-by":"crossref","first-page":"28885","DOI":"10.1074\/jbc.M109.052407","article-title":"Hepatocyte nuclear factor 1\u03b1 plays a critical role in PCSK9 gene transcription and regulation by the natural Hypocholesterolemic compound Berberine*","author":"Li","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2019.03.018_bb0270","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1248\/bpb.b14-00412","article-title":"Berberine up-regulates hepatic low-density lipoprotein receptor through Ras-independent but AMP-activated protein kinase-dependent Raf-1 activation","volume":"37","author":"Li","year":"2014","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.taap.2019.03.018_bb0275","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001588","article-title":"The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis","volume":"4","author":"Liao","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.taap.2019.03.018_bb0280","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","article-title":"Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice","volume":"17","author":"Lin","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.taap.2019.03.018_bb0285","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1161\/CIRCULATIONAHA.115.015308","article-title":"Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice","volume":"131","author":"Lin","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.taap.2019.03.018_bb0290","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1161\/CIRCRESAHA.117.305262","article-title":"Thrombospondin-1 (TSP1) contributes to the development of vascular inflammation by regulating monocytic cell motility in mouse models of abdominal aortic aneurysm","volume":"117","author":"Liu","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.taap.2019.03.018_bb0295","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2016.14568","article-title":"Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis","volume":"316","author":"Lotta","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.taap.2019.03.018_bb0300","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1373\/clinchem.2011.165191","article-title":"Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture","volume":"57","author":"Mayne","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.taap.2019.03.018_bb0305","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0006-291X(88)80832-5","article-title":"Yeast KEX2 genes encodes an endopeptidase homologous to subtilisin-like serine proteases","volume":"156","author":"Mizuno","year":"1988","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2019.03.018_bb0310","series-title":"Emerging Roles of PCSK9","author":"Moore","year":"2016"},{"key":"10.1016\/j.taap.2019.03.018_bb0315","first-page":"e29","article-title":"Heart disease and stroke statistics--2015 update: a report from the American Heart Association","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.taap.2019.03.018_bb0320","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.2353\/ajpath.2010.090014","article-title":"A role for the high-density lipoprotein receptor SR-B1 in synovial inflammation via serum amyloid-A","volume":"176","author":"Mullan","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.taap.2019.03.018_bb0325","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/bj3270625","article-title":"Furin: a mammalian subtilisin\/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins","volume":"327","author":"Nakayama","year":"1997","journal-title":"Biochem. J."},{"key":"10.1016\/j.taap.2019.03.018_bb0330","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/cvr\/cvw194","article-title":"Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering","volume":"112","author":"Norata","year":"2016","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.taap.2019.03.018_bb0335","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1136\/annrheumdis-2012-201305","article-title":"Serum immune complex containing thrombospondin-1: a novel biomarker for early rheumatoid arthritis","author":"Ohyama","year":"2012","journal-title":"Ann. Rheum. Dis., England"},{"key":"10.1016\/j.taap.2019.03.018_bb0340","doi-asserted-by":"crossref","first-page":"50630","DOI":"10.1074\/jbc.M410077200","article-title":"Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver","volume":"279","author":"Park","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2019.03.018_bb0345","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1194\/jlr.M035352","article-title":"CD36, but not G2A, modulates efferocytosis, inflammation, and fibrosis following bleomycin-induced lung injury","volume":"54","author":"Parks","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.taap.2019.03.018_bb0350","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1742-1241.2009.02220.x","article-title":"The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better","volume":"64","author":"Peters","year":"2010","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.taap.2019.03.018_bb0355","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/ard.59.6.448","article-title":"Expression of thrombospondin-1 and its receptor CD36 in human osteoarthritic cartilage","volume":"59","author":"Pfander","year":"2000","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.taap.2019.03.018_bb0360","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2015.09.032","article-title":"Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies","volume":"243","author":"Pirillo","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.taap.2019.03.018_bb0365","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11883-018-0715-0","article-title":"The interplay of lipids, lipoproteins, and immunity in atherosclerosis","volume":"20","author":"Pirillo","year":"2018","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.taap.2019.03.018_bb0370","first-page":"1135","article-title":"The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol","volume":"7","author":"Poirier","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.taap.2019.03.018_bb0375","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1093\/eurheartj\/ehx165","article-title":"Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives","volume":"39","author":"Poller","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.taap.2019.03.018_bb0380","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.118.034645","article-title":"Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy","volume":"138","author":"Pradhan","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.taap.2019.03.018_bb0385","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1194\/jlr.M700071-JLR200","article-title":"Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis","volume":"48","author":"Qian","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.taap.2019.03.018_bb0390","doi-asserted-by":"crossref","first-page":"320724","DOI":"10.1155\/2013\/320724","article-title":"Adipo-myokines: two sides of the same coin--mediators of inflammation and mediators of exercise","volume":"2013","author":"Raschke","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.taap.2019.03.018_bb0395","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/1874192401812010029","article-title":"Reduction of vascular inflammation, LDL-C, or both for the protection from cardiovascular events?","volume":"12","author":"Reklou","year":"2018","journal-title":"Open Cardiovasc. Med. J."},{"key":"10.1016\/j.taap.2019.03.018_bb0400","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.yjmcc.2015.03.009","article-title":"RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form","volume":"82","author":"Rocha","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.taap.2019.03.018_bb0405","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/annrheumdis-2012-202914","article-title":"Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus","volume":"73","author":"Ronda","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.taap.2019.03.018_bb0410","series-title":"Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events","author":"Sabatine","year":"2015"},{"key":"10.1016\/j.taap.2019.03.018_bb0415","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1089\/dna.2007.0667","article-title":"A novel splicing variant of proprotein convertase subtilisin\/kexin type 9","volume":"27","author":"Schmidt","year":"2008","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.taap.2019.03.018_bb0420","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.taap.2019.03.018_bb0425","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-1-61779-204-5_3","article-title":"The proprotein convertases, 20 years later","volume":"768","author":"Seidah","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.taap.2019.03.018_bb0430","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.taap.2019.03.018_bb0435","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2019.03.018_bb0440","series-title":"PCSK9","author":"Seidah","year":"2014"},{"key":"10.1016\/j.taap.2019.03.018_bb0445","doi-asserted-by":"crossref","unstructured":"Seidah, N.G., Abifadel, M., Prost, S., Boileau, C., Prat, A., Touyz, R.M., 2017. The proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on proprotein convertase subtilisin\/kexin 9.","DOI":"10.1124\/pr.116.012989"},{"key":"10.1016\/j.taap.2019.03.018_bb0450","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/13813450600711540","article-title":"Pathways leading to muscle insulin resistance--the muscle--fat connection","volume":"112","author":"Sell","year":"2006","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.taap.2019.03.018_bb0455","doi-asserted-by":"crossref","first-page":"937843","DOI":"10.1155\/2011\/937843","article-title":"Targeting nuclear hormone receptors: PPARalpha agonists as potential disease-modifying drugs for rheumatoid arthritis","volume":"2011","author":"Shirinsky","year":"2011","journal-title":"Int. J. Rheumatol."},{"issue":"Suppl. 2","key":"10.1016\/j.taap.2019.03.018_bb0460","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.3949\/ccjm.76.s2.06","article-title":"Inflammation, atherosclerosis, and arterial thrombosis: role of the scavenger receptor CD36","volume":"76","author":"Silverstein","year":"2009","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.taap.2019.03.018_bb0465","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ni.1836","article-title":"CD36 ligands promote sterile inflammation through assembly of a toll-like receptor 4 and 6 heterodimer","volume":"11","author":"Stewart","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.taap.2019.03.018_bb0470","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3899\/jrheum.141292","article-title":"Upregulation of thrombospondin 1 expression in synovial tissues and plasma of rheumatoid arthritis: role of transforming growth factor-beta1 toward fibroblast-like synovial cells","volume":"42","author":"Suzuki","year":"2015","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.taap.2019.03.018_bb0475","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1253\/circj.CJ-15-0999","article-title":"Lipoprotein(a) in familial hypercholesterolemia with proprotein convertase subtilisin\/kexin type 9 (PCSK9) gain-of-function mutations","volume":"80","author":"Tada","year":"2016","journal-title":"Circ. J."},{"key":"10.1016\/j.taap.2019.03.018_bb0480","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nri3793","article-title":"Cholesterol, inflammation and innate immunity","volume":"15","author":"Tall","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.taap.2019.03.018_bb0485","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1002\/jcp.27254","article-title":"PCSK9: a novel inflammation modulator in atherosclerosis?","volume":"234","author":"Tang","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.taap.2019.03.018_bb0490","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/cvr\/cvw053","article-title":"Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms","volume":"110","author":"Tavori","year":"2016","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.taap.2019.03.018_bb0495","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.numecd.2011.06.002","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition","volume":"21","author":"Tibolla","year":"2011","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.taap.2019.03.018_bb0500","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/1874192401105010064","article-title":"Dyslipidaemia in rheumatological autoimmune diseases","author":"Toms","year":"2011","journal-title":"Open Cardiovasc. Med. J."},{"key":"10.1016\/j.taap.2019.03.018_bb0505","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2174\/1389202911314050010","article-title":"Genetics of the first seven proprotein convertase enzymes in health and disease","volume":"14","author":"Turpeinen","year":"2013","journal-title":"Curr. Genomics"},{"key":"10.1016\/j.taap.2019.03.018_bb0510","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.taap.2015.06.017","article-title":"Thymoquinone inhibits TNF-\u03b1-induced inflammation and cell adhesion in rheumatoid arthritis synovial fibroblasts by ASK1 regulation","volume":"287","author":"Umar","year":"2015","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2019.03.018_bb0515","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2015.03.099","article-title":"PCSK9 inhibitors: novel therapeutic agents for the treatment of hypercholesterolemia","volume":"763","author":"Verbeek","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.taap.2019.03.018_bb0520","doi-asserted-by":"crossref","DOI":"10.1177\/1535370213503262","article-title":"Plasma from rheumatoid arthritis patients promotes pro-atherogenic cholesterol transport gene expression in THP-1 human macrophages","volume":"238","author":"Voloshyna","year":"2013","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.taap.2019.03.018_bb0525","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/MCC.0000000000000351","article-title":"Role of lipoproteins and proprotein convertase subtilisin\/kexin type 9 in endotoxin clearance in sepsis","volume":"22","author":"Walley","year":"2016","journal-title":"Curr. Opin. Crit. Care"},{"key":"10.1016\/j.taap.2019.03.018_bb0530","doi-asserted-by":"crossref","first-page":"258ra143","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK9 is a critical regulator of the innate immune response and septic shock outcome","volume":"6","author":"Walley","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.taap.2019.03.018_bb0535","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1164\/rccm.201505-0876CI","article-title":"The central role of proprotein convertase subtilisin\/kexin type 9 in septic pathogen lipid transport and clearance","volume":"192","author":"Walley","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.taap.2019.03.018_bb0540","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1124\/pr.111.005074","article-title":"CC chemokine receptors and chronic inflammation--therapeutic opportunities and pharmacological challenges","volume":"65","author":"White","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.taap.2019.03.018_bb0545","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/cpt.263","article-title":"PCSK9 inhibitors: are we on the verge of a breakthrough?","volume":"98","author":"Yang","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2019.03.018_bb0550","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.intimp.2015.01.005","article-title":"Fibroblast growth factor 21 (FGF21) ameliorates collagen-induced arthritis through modulating oxidative stress and suppressing nuclear factor-kappa B pathway","volume":"25","author":"Yu","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.taap.2019.03.018_bb0555","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2019.03.018_bb0560","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/annrheumdis-2013-204715","article-title":"The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis","volume":"73","author":"Zhang","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.taap.2019.03.018_bb0565","series-title":"New Clinical Data from Phase 1 Trial with ALN-PCSsc Confirms Potential for Bi-Annual Dosing | Alnylam","year":"2016"},{"key":"10.1016\/j.taap.2019.03.018_bb0570","series-title":"Its Investigational PCSK9 Inhibitor | Pfizer: One of the World's Premier Biopharmaceutical Companies","year":"2016"},{"key":"10.1016\/j.taap.2019.03.018_bb0575","series-title":"The Medicines Company and Alnylam Pharmaceuticals Present Positive Results from ORION-1 Phase 2 Study of Inclisiran (formerly PCSK9si) | The Medicines Company","year":"2016"},{"key":"10.1016\/j.taap.2019.03.018_bb0580","series-title":"Catabasis \u2013 Investors \u2013 Press Release","year":"2017"},{"key":"10.1016\/j.taap.2019.03.018_bb0585","series-title":"Novartis Licenses Its Anti-PCSK9 to Sepsis Startup Cyon | FierceBiotech","year":"2017"},{"key":"10.1016\/j.taap.2019.03.018_bb0590","series-title":"Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects \u2013 Full Text View \u2013 ClinicalTrials.gov","year":"2017"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X19301085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X19301085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T05:03:57Z","timestamp":1606971837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X19301085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":117,"alternative-id":["S0041008X19301085"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2019.03.018","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging role of proprotein convertase subtilisin\/kexin type-9 (PCSK-9) in inflammation and diseases","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2019.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}